DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells

Endocrine-Related Cancer

Volumn 20, Issue 1, 2013, Pages 23-37

  Degl'Innocenti, Debora ^a   Romeo, Paola ^a   Tarantino, Eva ^a   Sensi, Marialuisa ^a   Cassinelli, Giuliana ^a   Catalano, Veronica ^a   Lanzi, Cinzia ^a   Perrone, Federica ^a   Pilotti, Silvana ^a   Seregni, Ettore ^a   Pierotti, Marco A ^a   Greco, Angela ^a   Borrello, Maria Grazia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Dual specificity phosphatase; DUSP6 MKP3; DUSPs; ERK1 2; Papillary Thyroid Carcinoma; Thyroid carcinoma

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; PYRROLIDINE DITHIOCARBAMATE;

ADULT; AGED; ARTICLE; BRANCHING MORPHOGENESIS; CANCER CELL; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA ISOLATION; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; ONCOGENE; OUTCOME ASSESSMENT; POORLY DIFFERENTIATED THYROID CANCER; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA INTERFERENCE; UPREGULATION; WESTERN BLOTTING;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, PAPILLARY; CELL ADHESION; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DUAL SPECIFICITY PHOSPHATASE 6; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYROID GLAND; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84874069368     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0078     Document Type: Article

References (52)

1. Arkell RS, Dickinson RJ, Squires M, Hayat S, Keyse SM & Cook SJ 2008 DUSP6/MKP-3 inactivates ERK1/2 but fails to bind and inactivate ERK5. Cellular Signalling 20 836-843. (doi:10.1016/j.cellsig.2007.12.014)
2. Arora N, Scognamiglio T, Lubitz CC, Moo TA, Kato MA, Zhu B, Zarnegar R, Chen YT & Fahey TJ, III 2009 Identification of borderline thyroid tumors by gene expression array analysis. Cancer 115 5421-5431. (doi:10.1002/cncr.24616)
3. Bejarano PA, Nikiforov YE, Swenson ES & Biddinger PW 2000 Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms. Applied Immunohistochemistry & Molecular Morphology 8 189-194. (doi:10.1097/00022744-200009000-00004)
4. Bermudez O, Pages G & Gimond C 2010 The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. American Journal of Physiology. Cell Physiology 299 C189-C202. (doi:10.1152/ ajpcell.00347.2009)
5. Bermudez O, Jouandin P, Rottier J, Bourcier C, Pages G & Gimond C 2011 Post-transcriptional regulation of the DUSP6/MKP-3 phosphatase by MEK/ERK signaling and hypoxia. Journal of Cellular Physiology 226 276-284. (doi:10.1002/jcp.22339)
6. Bloethner S, Chen B, Hemminki K, Muller-Berghaus J, Ugurel S, Schadendorf D & Kumar R 2005 Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis 26 1224-1232. (doi:10.1093/carcin/bgi066)
7. Borrello MG, Alberti L, Fischer A, Degl'Innocenti D, Ferrario C, Gariboldi M, Marchesi F, Allavena P, Greco A, Collini P et al. 2005 Induction of a proinflammatory programme in normal human thyrocytes by the RET/PTC1 oncogene. PNAS 102 14825-14830. (doi:10.1073/pnas. 0503039102)
8. Camps M, Nichols A, Gillieron C, Antonsson B, Muda M, Chabert C, Boschert U & Arkinstall S 1998 Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase. Science 280 1262-1265. (doi:10.1126/science. 280.5367.1262)
9. Cassinelli G, Favini E, Degl'Innocenti D, Salvi A, De PG, Pierotti MA, Zunino F, Borrello MG & Lanzi C 2009 RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and b-catenin nuclear translocation. Neoplasia 11 10-21.
10. Chambard JC, Lefloch R, Pouyssegur J & Lenormand P 2007 ERK implication in cell cycle regulation. Biochimica et Biophysica Acta 1773 1299-1310. (doi:10.1016/j.bbamcr.2006.11.010)
11. Chevillard S, Ugolin N, Vielh P, Ory K, Levalois C, Elliott D, Clayman GL & Naggar AK 2004 Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clinical Cancer Research 10 6586-6597. (doi:10.1158/1078-0432.CCR-04-0053)
12. Croonquist PA, Linden MA, Zhao F & Van Ness BG 2003 Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells. Blood 102 2581-2592. (doi:10.1182/blood-2003-04-1227)
13. Curcio F, Ambesi-Impiombato FS, Perrella G & Coon HG 1994 Long-term culture and functional characterization of follicular cells from adult normal human thyroids. PNAS 91 9004-9008. (doi:10.1073/pnas.91. 19.9004)
14. Davies L & Weleh HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. Journal of the American Medical Association 295 2164-2167. (doi:10.1001/jama.295.18.2164)
15. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W et al. 2002 Mutations of the BRAF gene in human cancer. Nature 417 949-954. (doi:10.1038/ nature00766)
16. Degl'Innocenti D, Alberti C, Castellano G, Greco A, Miranda C, Pierotti MA, Seregni E, Borrello MG, Canevari S & Tomassetti A 2010 Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomas. PLoS ONE 5 e12701. (doi:10.1371/journal.pone.0012701)
17. Delellis RA, Lloyd RV, Heitz PU & Eng C 2004 In World Health Organization classification of tumours. Pathology and genetics of tumors of endocrine organs. Eds RA Delellis, RV Lloyd, PU Heitz & C Eng. Lyon, France: IARC Press.
18. Delys L, Detours V, Franc B, Thomas G, Bogdanova T, Tronko M, Libert F, Dumont JE & Maenhaut C 2007 Gene expression and the biological phenotype of papillary thyroid carcinomas. Oncogene 26 7894-7903. (doi:10.1038/sj.onc. 1210588)
19. Eszlinger M, Krohn K, Kukulska A, Jarzab B & Paschke R 2007 Perspectives and limitations of microarray-based gene expression profiling of thyroid tumors. Endocrine Reviews 28 322-338. (doi:10.1210/er.2006- 0047)
20. Fjeld CC, Rice AE, Kim Y, Gee KR & Denu JM 2000 Mechanistic basis for catalytic activation of mitogen-activated protein kinase phosphatase 3 by extracellular signal-regulated kinase. Journal of Biological Chemistry 275 6749-6757. (doi:10.1074/jbc.275.10.6749)
21. Fontaine JF,Mirebeau-Prunier D, RaharijaonaM, Franc B, Triau S, Rodien P, Goeau-Brissonniere O, Karayan-Tapon L, Mello M, Houlgatte R et al. 2009 Increasing the number of thyroid lesions classes in microarray analysis improves the relevance of diagnostic markers. PLoS ONE 4 e7632. (doi:10.1371/journal. pone.0007632)
22. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S et al. 2004 Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23 7436-7440. (doi:10.1038/sj.onc.1207980)
23. Furukawa T, Sunamura M, Motoi F, Matsuno S & Horii A 2003 Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. American Journal of Pathology 162 1807-1815. (doi:10.1016/ S0002-9440(10)64315-5)
24. Furukawa T, Fujisaki R, Yoshida Y, Kanai N, Sunamura M, Abe T, Takeda K, Matsuno S & Horii A 2005 Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Modern Pathology 18 1034-1042. (doi:10.1038/modpathol.3800383)
25. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K et al. 2005 Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24 6646-6656. (doi:10.1038/sj.onc.1208822)
26. Greco A, Borrello MG, Miranda C, Degl'Innocenti D & Pierotti MA 2009 Molecular pathology of differentiated thyroid cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging 53 440-453.
27. Griffith OL,Melck A, Jones SJ & Wiseman SM 2006 Meta-analysis and metareview of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. Journal of Clinical Oncology 24 5043-5051. (doi:10.1200/JCO.2006.06.7330)
28. Groom LA, Sneddon AA, Alessi DR, Dowd S & Keyse SM 1996 Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. EMBO Journal 15 3621-3632.
29. Guarino V, Castellone MD, Avilla E & Melillo RM 2009 Thyroid cancer and inflammation. Molecular and Cellular Endocrinology 321 94-102. (doi:10.1016/j.mce.2009.10.003)
30. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C et al. 2001 Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. PNAS 98 15044-15049. (doi:10.1073/pnas.251547398)
31. Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, Oczko-Wojciechowska M, Wloch J, Czarniecka A, Chmielik E, Lange D et al. 2005 Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Research 65 1587-1597. (doi:10.1158/0008-5472.CAN-04-3078)
32. Lee JU, Huang S, Lee MH, Lee SE, RyuMJ, Kim SJ, Kim YK, Kim SY, Joung KH, Kim JM et al. 2012 Dual specificity phosphatase 6 as a predictor of invasiveness in papillary thyroid cancer. European Journal of Endocrinology 167 93-101. (doi:10.1530/EJE-12-0010)
33. Lonne GK, Masoumi KC, Lennartsson J & Larsson C 2009 Protein kinase Cdelta supports survival of MDA-MB-231 breast cancer cells by suppressing the ERK1/2 pathway. Journal of Biological Chemistry 284 33456-33465. (doi:10.1074/jbc.M109.036186)
34. Lu BC, Cebrian C, Chi X, Kuure S, Kuo R, Bates CM, Arber S, Hassell J, MacNeil L, Hoshi M et al. 2009 Etv4 and Etv5 are required downstream of GDNF and Ret for kidney branching morphogenesis. Nature Genetics 41 1295-1302. (doi:10.1038/ng.476)
35. Lucci MA, Orlandi R, Triulzi T, Tagliabue E, Balsari A & Villa-Moruzzi E 2010 Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors. Cellular Oncology 32 361-372.
36. MacKeigan JP, Murphy LO & Blenis J 2005 Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nature Cell Biology 7 591-600. (doi:10.1038/ ncb1258)
37. Messina S, Frati L, Leonetti C, Zuchegna C, Di ZE, Calogero A & Porcellini A 2011 Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas. Oncogene 30 3813-3820. (doi:10.1038/onc.2011. 99)
38. Miller KA, Yeager N, Baker K, Liao XH, Refetoff S & Di CA 2009 Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Research 69 3689-3694. (doi:10.1158/0008-5472.CAN-09-0024)
39. Muda M, Theodosiou A, Gillieron C, Smith A, Chabert C, Camps M, Boschert U, Rodrigues N, Davies K, Ashworth A et al. 1998 The mitogenactivated protein kinase phosphatase-3 N-terminal noncatalytic region is responsible for tight substrate binding and enzymatic specificity. Journal of Biological Chemistry 273 9323-9329. (doi:10.1074/jbc.273. 15.9323)
40. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T & Yamashita S 2003 Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. Journal of Clinical Endocrinology and Metabolism 88 4393-4397. (doi:10.1210/jc.2003-030305)
41. Okudela K, Yazawa T, Ishii J, Woo T, Mitsui H, Bunai T, Sakaeda M, ShimoyamadaH, Sato H, TajiriMet al. 2009 Down-regulation of FXYD3 expression in human lung cancers: its mechanism and potential role in carcinogenesis. American Journal of Pathology 175 2646-2656. (doi:10.2353/ajpath.2009.080571)
42. Quyun C, Ye Z, Lin SC & Lin B 2010 Recent patents and advances in genomic biomarker discovery for colorectal cancers. Recent Patents on DNA & Gene Sequences 4 86-93. (doi:10.2174/187221510793205764)
43. Roccato E, Miranda C, Ranzi V, Gishizky ML, Pierotti MA & Greco A 2002 Biological activity of the thyroid TRK-T3 oncogene requires signaling through Shc. British Journal of Cancer 87 645-653. (doi:10.1038/sj.bjc. 6600544)
44. Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, Ugolini C, Miccoli P, Basolo F, Castellone MD, Cirafici AM et al. 2007 A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Research 67 10148-10158. (doi:10.1158/0008-5472.CAN- 07-1887)
45. Santarpia L, El-Naggar AK, Cote GJ, Myers JN & Sherman SI 2008 Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. Journal of Clinical Endocrinology and Metabolism 93 278-284. (doi:10.1210/jc.2007-1076)
46. Santoro M, Papotti M, Chiappetta G, Garcia-Rostan G, Volante M, Johnson C, Camp RL, Pentimalli F, Monaco C, Herrero A et al. 2002 RET activation and clinicopathologic features in poorly differentiated thyroid tumors. Journal of Clinical Endocrinology and Metabolism 87 370-379. (doi:10.1210/jc.87.1.370)
47. Sobin LH, Gospodarowicz MK & Wittekind CH 2009 Thyroid gland-rules for classification. In UICC TNM classification of malignant tumors, 7th edn, pp 58-62. Eds LH Sobin, MK Gospodarowicz MK & CH Wittekind. New York, NY, USA: Wiley-Liss.
48. Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-Duvaz D, Springer CJ & Marais R 2004 V599EB-RAF is an oncogene in melanocytes. Cancer Research 64 2338-2342. (doi:10.1158/0008-5472. CAN-03-3433)
49. Wortzel I & Seger R 2011 The ERK cascade: distinct functions within various subcellular organelles. Genes & Cancer 2 195-209. (doi:10.1177/ 1947601911407328)
50. Wu Z, Jiao P, Huang X, Feng B, Feng Y, Yang S, Hwang P, Du J, Nie Y, Xiao G et al. 2010 MAPK phosphatase-3 promotes hepatic gluconeogenesis through dephosphorylation of forkhead box O1 in mice. Journal of Clinical Investigation 120 3901-3911. (doi:10.1172/JCI43250)
51. Zhang Z, Kobayashi S, Borczuk AC, Leidner RS, Laframboise T, Levine AD & Halmos B 2010 Dual specificity phosphatase 6 (DUSP6) is an ETSregulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis 31 577-586. (doi:10.1093/carcin/ bgq020)
52. Zhang YY, Wu JW & Wang ZX 2011 Mitogen-activated protein kinase (MAPK) phosphatase 3-mediated cross-talk between MAPKs ERK2 and p38alpha. Journal of Biological Chemistry 286 16150-16162. (doi:10.1074/jbc.M110.203786)